- $79.49m
- -$122.17m
- $149.96m
- 16
- 63
- 23
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.68 | ||
| Price to Tang. Book | 0.68 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.53 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.06% | ||
| Return on Equity | -49.85% | ||
| Operating Margin | -49.56% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 104.88 | 77.45 | 151.94 | 58.75 | 149.96 | 37.43 | 67.7 | 18.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Directors
- Paulo Costa NEC (71)
- Scott Koenig PRE (69)
- James Karrels CFO (54)
- Ezio Bonvini SVP (67)
- Stephen Eck SVP (66)
- Eric Risser SVP (48)
- Thomas Spitznagel SVP (54)
- Jeffrey Peters VPR (50)
- Lynn Cilinski VPR (63)
- Karen Ferrante IND (63)
- Edward Hurwitz IND (57)
- Scott Jackson IND (56)
- Federica O'Brien IND (63)
- Jay Siegel IND (68)
- David Stump IND (71)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 14th, 2000
- Public Since
- October 10th, 2013
- No. of Shareholders
- 52
- No. of Employees
- 341
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 63,090,323
- Address
- 9704 Medical Center Drive, ROCKVILLE, 20850
- Web
- https://www.macrogenics.com/
- Phone
- +1 3012515172
- Auditors
- Ernst & Young LLP
Upcoming Events for MGNX
MacroGenics Inc Annual Shareholders Meeting
MacroGenics Inc Annual Shareholders Meeting
Q2 2025 MacroGenics Inc Earnings Release
Similar to MGNX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the MacroGenics share price?
As of Today at 21:50 UTC, shares in MacroGenics are trading at $1.26. This share price information is delayed by 15 minutes.
How has the MacroGenics share price performed this year?
Shares in MacroGenics last closed at $1.26 and the price had moved by -92.17% over the past 365 days. In terms of relative price strength the MacroGenics share price has underperformed the S&P500 Index by -92.64% over the past year.
What are the analyst and broker recommendations for MacroGenics?
The overall consensus recommendation for MacroGenics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the MacroGenics dividend yield?
MacroGenics does not currently pay a dividend.
Does MacroGenics pay a dividend?
MacroGenics does not currently pay a dividend.
When does MacroGenics next pay dividends?
MacroGenics does not currently pay a dividend.
How do I buy MacroGenics shares?
To buy shares in MacroGenics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of MacroGenics?
As of the previous close price of $1.26, shares in MacroGenics had a market capitalisation of $79.49m.
Where are MacroGenics shares listed?
Here are the trading details for MacroGenics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MGNX
What kind of share is MacroGenics?
Based on an overall assessment of its quality, value and momentum MacroGenics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a MacroGenics share price forecast for 2025?
The analyst consensus target price for shares in MacroGenics is $5.80. That is 360.32% above the last closing price of $1.26.
Analysts covering MacroGenics currently have a consensus Earnings Per Share (EPS) forecast of -$2.89 for the next financial year.
Find out moreWhat is the trend in the MacroGenics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MacroGenics. Over the past six months, its share price has underperformed the S&P500 Index by -65.18%.
As of the last closing price of $1.26, shares in MacroGenics were trading -61.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the MacroGenics PE Ratio?
The MacroGenics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of MacroGenics?
MacroGenics' management team is headed by:
- Paulo Costa - NEC
- Scott Koenig - PRE
- James Karrels - CFO
- Ezio Bonvini - SVP
- Stephen Eck - SVP
- Eric Risser - SVP
- Thomas Spitznagel - SVP
- Jeffrey Peters - VPR
- Lynn Cilinski - VPR
- Karen Ferrante - IND
- Edward Hurwitz - IND
- Scott Jackson - IND
- Federica O'Brien - IND
- Jay Siegel - IND
- David Stump - IND